Skip to main content
. 2019 Jan 4;12(3):523–538. doi: 10.1016/j.tranon.2018.11.011

Figure 7.

Figure 7

Nivolumab pre- and posttreatment head CTs with contrast in a patient with primary refractory PCNSL. (Left) The contrast-enhancing lesion before treatment with nivolumab. (Middle) Complete response following 2 months of therapy with nivolumab. (Right) Continued complete response 13 months following initiation of therapy. This figure is reprinted from Nayak et al.